Tosin Lambe1, Emma Frew2, Natalie J Ives3, Rebecca L Woolley3, Carole Cummins4, Elizabeth A Brettell3, Emma N Barsoum3, Nicholas J A Webb5. 1. Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK. 2. Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK. e.frew@bham.ac.uk. 3. Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK. 4. Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 5. Department of Paediatric Nephrology and NIHR Manchester Clinical Research Facility, Manchester Academic Health Science Centre, Royal Manchester Children's Hospital, Manchester, UK.
Abstract
BACKGROUND: The Paediatric Quality of Life Inventory (PedsQL™) questionnaire is a widely used, generic instrument designed for measuring health-related quality of life (HRQoL); however, it is not preference-based and therefore not suitable for cost-utility analysis. The Child Health Utility Index-9 Dimension (CHU-9D), however, is a preference-based instrument that has been primarily developed to support cost-utility analysis. OBJECTIVE: This paper presents a method for estimating CHU-9D index scores from responses to the PedsQL™ using data from a randomised controlled trial of prednisolone therapy for treatment of childhood corticosteroid-sensitive nephrotic syndrome. METHODS:HRQoL data were collected from children at randomisation, week 16, and months 12, 18, 24, 36 and 48. Observations on children aged 5 years and older were pooled across all data collection timepoints and were then randomised into an estimation (n = 279) and validation (n = 284) sample. A number of models were developed using the estimation data before internal validation. The best model was chosen using multi-stage selection criteria. RESULTS: Most of the models developed accurately predicted the CHU-9D mean index score. The best performing model was a generalised linear model (mean absolute error = 0.0408; mean square error = 0.0035). The proportion of index scores deviating from the observed scores by < 0.03 was 53%. CONCLUSIONS: The mapping algorithm provides an empirical tool for estimating CHU-9D index scores and for conducting cost-utility analyses within clinical studies that have only collected PedsQL™ data. It is valid for children aged 5 years or older. Caution should be exercised when using this with children younger than 5 years, older adolescents (> 13 years) or patient groups with particularly poor quality of life. ISRCTN REGISTRY NO: 16645249.
RCT Entities:
BACKGROUND: The Paediatric Quality of Life Inventory (PedsQL™) questionnaire is a widely used, generic instrument designed for measuring health-related quality of life (HRQoL); however, it is not preference-based and therefore not suitable for cost-utility analysis. The Child Health Utility Index-9 Dimension (CHU-9D), however, is a preference-based instrument that has been primarily developed to support cost-utility analysis. OBJECTIVE: This paper presents a method for estimating CHU-9D index scores from responses to the PedsQL™ using data from a randomised controlled trial of prednisolone therapy for treatment of childhood corticosteroid-sensitive nephrotic syndrome. METHODS: HRQoL data were collected from children at randomisation, week 16, and months 12, 18, 24, 36 and 48. Observations on children aged 5 years and older were pooled across all data collection timepoints and were then randomised into an estimation (n = 279) and validation (n = 284) sample. A number of models were developed using the estimation data before internal validation. The best model was chosen using multi-stage selection criteria. RESULTS: Most of the models developed accurately predicted the CHU-9D mean index score. The best performing model was a generalised linear model (mean absolute error = 0.0408; mean square error = 0.0035). The proportion of index scores deviating from the observed scores by < 0.03 was 53%. CONCLUSIONS: The mapping algorithm provides an empirical tool for estimating CHU-9D index scores and for conducting cost-utility analyses within clinical studies that have only collected PedsQL™ data. It is valid for children aged 5 years or older. Caution should be exercised when using this with children younger than 5 years, older adolescents (> 13 years) or patient groups with particularly poor quality of life. ISRCTN REGISTRY NO: 16645249.
Authors: Nalin Payakachat; Kent H Summers; Andreas M Pleil; Matthew M Murawski; Joseph Thomas; Kristofer Jennings; James G Anderson Journal: Qual Life Res Date: 2009-06-19 Impact factor: 4.147
Authors: Peymane Adab; Miranda J Pallan; Emma R Lancashire; Karla Hemming; Emma Frew; Tania Griffin; Timothy Barrett; Raj Bhopal; Janet E Cade; Amanda Daley; Jonathan Deeks; Joan Duda; Ulf Ekelund; Paramjit Gill; Eleanor McGee; Jayne Parry; Sandra Passmore; Kar Keung Cheng Journal: BMC Public Health Date: 2015-05-13 Impact factor: 3.295
Authors: Nafsika Afentou; Emma Frew; Samir Mehta; Natalie J Ives; Rebecca L Woolley; Elizabeth A Brettell; Adam R Khan; David V Milford; Detlef Bockenhauer; Moin A Saleem; Angela S Hall; Ania Koziell; Heather Maxwell; Shivaram Hegde; Eric Finlay; Rodney D Gilbert; Caroline Jones; Karl McKeever; Wendy Cook; Nicholas J A Webb; Martin T Christian Journal: Pharmacoecon Open Date: 2022-06-22
Authors: Hans Krueger; Sylvia Robinson; Trevor Hancock; Richard Birtwhistle; Jane A Buxton; Bonnie Henry; Jennifer Scarr; John J Spinelli Journal: BMC Health Serv Res Date: 2022-04-26 Impact factor: 2.908
Authors: Izabella Orzechowska; M Zia Sadique; Karen Thomas; Peter Davis; Kevin P Morris; Paul R Mouncey; Mark J Peters; Alvin Richards-Belle; Lyvonne N Tume; Padmanabhan Ramnarayan; David A Harrison Journal: Trials Date: 2020-10-31 Impact factor: 2.279